Francis Medical Advances FDA-Cleared Vanquish System With First Midwest Commercial Use

Francis Medical marked its eighth anniversary this week, reiterating its mission to deliver prostate cancer treatments that are “tough on cancer, gentle on patients.” The company tied its origins to the founder’s family experience with prostate cancer, emphasizing patient quality of life as a core design principle alongside urology expertise and engineering-driven innovation.

The company also underscored that its Vanquish Water Vapor Ablation System is FDA-cleared and restricted to prescription use, reinforcing its regulatory progress. Vanquish is designed to ablate targeted prostate tissue via high-energy sterile water vapor delivered through a transurethral approach, aiming to provide a minimally invasive treatment option in prostate care.

Francis Medical reported the first commercial, non-clinical trial use of the Vanquish system in the U.S. Midwest at High Pointe Surgery Center in Lake Elmo, Minnesota. The procedure, performed by Dr. Aaron Milbank of Minnesota Urology, marked the technology’s initial use in routine clinical practice in that region and signals an early transition from trials to commercial deployment.

This initial Midwest case suggests early traction in real-world adoption, which could support the shift from clinical validation toward revenue-generating procedures. Targeted engagement with Minnesota Urology and an outpatient surgery center highlights a go-to-market focus on key opinion leaders and high-volume procedural settings.

If Francis Medical can expand utilization beyond this site while demonstrating strong outcomes and workflow integration, it may strengthen its competitive position in minimally invasive prostate therapies. The company’s emphasis on collaboration with clinicians, partners, and patients, combined with its FDA-cleared platform, positions it for continued execution as it scales commercialization efforts.

Overall, the week highlighted both a milestone anniversary and tangible commercial progress for Francis Medical, underscoring momentum in bringing its Vanquish technology into broader clinical practice.